Longenesis Pitch Deck for TechChill

1. Investors
Pitch Deck
April 2022

2. About Us 3
The Opportunity 12
Our Digital Solutions 18
A-round & Projected Growth 28
Appendix (with selected case
studies)
35

3. ABOUT US
3

4. OUR MISSION
4
Longenesis: Unlocking a
healthier future by
modernizing medical data
Our mission is to help
modernize the
approach to human
health.
We firmly believe the
medical system of the
future is a collaborative
one.
A future where vital
and valuable medical
data is put to work to
find cures and
treatments while
remaining firmly within
the patient’s control.
A future where patients
can not only contribute
to medical
breakthroughs but also
experience
breakthrough, highly
personalized care for
themselves.

5. WHAT WE DO
5
Longenesis: Bridging
healthcare and life sciences
We provide solutions that make it easier for medical
data to be collected, analyzed, and utilized for better
care.
We bring an end-to-end, intuitive toolkit for Data
Discovery and Patient-Centric Engagement, while
being Privacy - and Ethics-by-Design at heart.

6. WHY US – 1/2
6
Ready to go, modular
solution covering the
whole life value chain
From data discovery to patient
engagement, our “plug and
play” solution is ready to be
deployed anywhere,
everywhere. (average
deployment time in less than a
month)
Collaborative, bespoke
approach to meet our
clients needs
With our flexible approach, we
work together with all the
involved stakeholders to meet
their needs and deploy the
most efficient and effective
solutions
Track record of
delivering at scale
Live national projects Latvia, EU
and UAE. Solutions ready to be
deployed in any country and on
any infrastructure. Already
covered more than 10
therapeutic areas and
onboarded more than 30
healthcare institutions
Exceptional adherence
and user experience
We adopt a user-centric
approach, while maintaining
compliance and prioritising
patient needs. Our latest
Engage projects have a growth
rate of >2 survey filled per day
Powered by Blockchain
Built to the highest security
standards, while providing clear
proof of patient consent for
data sharing and study
participation

7. WHY US – 2/2
7
Backed by sector
leaders in innovation
Such as AI drug discovery
company Insilico Medicine and
emerging technologies unicorn
The Bitfury Group
Wide team expertise
Team with multi-year global
experience in life sciences,
healthcare and technology.
Proud member of EIT Health, a
network of best-in-class health
innovators backed by the EU
Global network of
partners
Wide network of leading
researchers and clinical experts
as well as technology partners
to efficiently refine, validate and
implement our digital solutions
Awarded and valued in
the healthcare and
technology sector
Featured as a top startup to
watch by EU Startups, 50
Founders Battle. Proud finalists
for the Fair Healthdata
Challenge, Techhill, Medtech
Innovators

8. OUR SUCCESSFUL PROJECTS
8
2
• Government
Deployments
4+
• Big Pharma
Companies
10+
• Academic
Partners
Worldwide
250,000+
• Patients
Empowered
Worldwide
10+
• Disease
Domains
c.50%
• Reduction in
clinical trials
recruiting time

9. OUR RECENT ACHIEVEMENTS
9
featured in:
Finalist, 2019
Headstart COVID
winner

10. OUR TEAM
10

11. OUR ADVISORY BOARD
11
Alex Zhavoronkov, PhD – CEO and Co-founder of Insilico Medicine
Miro Venturi, PhD – Senior Vice President of Foundation Medicine
Dennis Bronnikov, MBA – Former VP of Roche, VP of Berkeley Lights
Leesa Soulodre, MBA – general partner of R3i Ventures

12. THE OPPORTUNITY
12

13. MAIN CHALLENGES WE ARE ADDRESSING
13
• Data is siloed and
unstructured
• Data organization is
time consuming,
taking months to
years
TECHNOLOGY
• Privacy risks from 3rd
party data access
• Compliant consent
curation
REGULATORY
• Patients are hard to
engage
• Patient engagement
expectations are not
met
LACK OF
PATIENT
ENGAGEMENT
Result - difficult to identify and engage patients
across multiple institutions.
9 out of 10 clinical sites
are overlooked in the
selection process
86%
Of trials are delayed
Clinical Trials Issues Example:

14. OUR SOLUTIONS
14
Two pillar approach:
Longenesis safely unlocks a healthier
future for humans.
We provide solutions that make it
easier for medical data to be collected,
analyzed, and utilized for better care…
…in one intuitive toolkit

15. TWO PILLAR APPROACH
15
Streamlines data sharing for clinical studies, bringing together healthcare and
life sciences organizations
Digital ecosystem platform that makes
data sharing for clinical studies easier.
Curator empowers clinical institutions,
researchers and patient organizations, to find
anonymized patient data for their studies,
overcoming the lengthy, ineffective and insecure
traditional identification process.
All data remains localized to its owners,
meaning sensitive medical information is
never shared with third-party servers or
stored in centralized databases

16. TWO PILLAR APPROACH
16
Engages patients through user-friendly education, surveys, simplified and
secured patient consent, while generating outcome based real world data
Digital platform which improves patient
management in clinical studies and
post-study activities with easy-to-use
survey creation tools, onboarding flows,
secured and compliant consent
management.
Enriches the standard of care and generates
value adding insights, leveraging real word
data analysis and support options.
Gives patients complete control over
their data, helping them feel
empowered to participate based on their
comfort level.

17. VALUE CREATION OPPORTUNITY FOR PHARMA
17
Earlier market launch
due to faster data
collection, study
completion(s) and
RWE insights
Reduced R&D costs
due to accelerated
participant recruitment
and increased
adherence with
engaging app
Additional market value
with improved patient
reach, additional digital
features and better
outcome based insights
C
O
S
T
R
E
V
E
N
U
E
M
A
R
K
E
T
L
A
U
N
C
H
T I M E
Drug Life-Cycle w/o Longenesis
C
O
M
P
E
T
I
T
O
R
/
G
E
N
E
R
I
C
E
N
T
R
Y
Drug Life-Cycle w/ Longenesis
Greater & sustained market
share
due to differentiated
offering and
enhanced engagement
1 2 3 4
1
2
3
4

18. OUR DIGITAL SOLUTIONS
18

19. OUR ECOSYSTEM
19
DATA
DISCOVERY
ENGAGEMENT
DATA PUBLISHERS
(Biobanks, Hospitals,
Biotech, Research
Groups)
PARTNERS/SPONSORS
(Academic Institutions, Pharma,
CRO, Research Groups, AI
Companies, Governmental
Organizations)
Biomedical fully
anonymized metadata
Surveys, Risk stratification, Analysis,
Complications and Side-effect
monitoring, Consent Management
• Platform providing real-time,
borderless, biomedical data or/and
patient identification, ensuring data
privacy and security and following
bioethics compliance
• Centralized meta-data curation
and discovery ecosystem with
decentralized data storage
• Robust solution for proactive full
patient engagement cycle into
prospective studies and multi-
channel data gathering and
personalized feedback, driving Real
World Data (RWD) collection
empowering smarter decisions
The value added by our solutions

20. DATA DISCOVERY WITH CURATOR
1 YEAR OF WORK IN DAYS. ENABLING REAL-TIME DATA DISCOVERY, WHILE DATA STAYS LOCAL
20
Identify patients in existing
healthcare provider
network
Discover new clinical sites fit
for research
Send direct data or patient
access requests straight to
clinical sites
1
2
3

21. WHY METADATA
STATISTICAL OVERVIEW OF SITE’S PATIENT POPULATION WITH NO PHI OR DATA INGESTION
21
Curator operates with anonymized
statistical patient information without
PHI, uploaded directly by sites
themselves
• Health data always stays local
• No PHI is accessed
• No EMR integrations or data
ingestion is performed

22. WHY CURATOR
22
•Non-invasive
•No privacy risks
•Uses anonymized
metadata
Patient-
centered
•Takes 1-2 days to
onboard a site
•Allows exports from any
EMR
Easy to use
•Extensive library of 30+
clinical sites in EU and
MENA available
Wide-
reaching
•Explores the patient
population at a new
clinical site in just hours
•Rapidly identify datasets
and engage potential
study participants
Fast and
effective

23. OVERVIEW OF ENGAGE FUNCTIONALITIES
23
VALUE ADDED
CLINICAL
TRIALS
MARKETED
DRUGS
DEPLOYMENT EXAMPLES
End-to-end dynamic
consent management
Full cycle of consent registration and management, as
well as biomedical/clinical data processing
Ready to be integrated into already existing interfaces, or
to be used as stand-alone, white-labelled solution.
Real-time instrument for consent review and audit,
ensuring privacy and protection
End-to-end consent management
for prospective study onboarding
for National Population Genome
program in the Middle East,
Real World Data
(RWD) collection
empowering smarter
decisions
Dynamic participant-centric interface for RWD collection
and personalized reporting, questionnaires and risk
assessments
Wider engagement possibilities, higher retention rates,
simplified process, as well as faster insights from patient-
reported data.
COVID-19 population studies,
personalized breast cancer-
related risk assessment, other
disease-specific QoL
Type 1 diabetes research study
with leading med-tech and patient
organizations to launch a new
patient-centric engagement
mechanism

24. PATIENT-CENTRIC PATIENT ENGAGEMENT
PATIENT-CENTRICITY BY DESIGN
24
Creates rapid participant /patient
engagement experience at the clinical
site level and/or for marketed drugs
Allows dynamic consent management,
pre-screening, questionnaires, risk
assessments and RWD generation
Enriches Curator with anonymized
metadata

25. DYNAMIC E-CONSENT MANAGEMENT
EMPOWERING PATIENTS WITH ETHICS BY DESIGN
25
A real-time instrument for consent
audit for clinical researchers
Empowering patients with a right to
decide where, how and why the data
will be used
API ready to be integrated in any
interface

26. WHY ENGAGE
26
• Run patient-centric onboarding
and RWD generation from
participants in existing and
newly discovered clinical sites,
as well as for marketed drugs
• Non-invasive
Patient-
centered
• Experience intuitive ease of use
Easy to use
• Meet evolving patient
expectations for proactive
engagement
Better proactive
engagement
• Rapidly identify datasets and
engage potential study
participants, significantly
reducing time and costs of
clinical trials
• Generates outcome-based
insights for marketed drugs,
ultimately increasing drugs
revenues and market share
Fast and
effective

27. REGULATORY STATUS
27
Engagement Module
• Adhering to HIPAA/GDPR/PIPA
framework
• Regional cloud deployments
• Working towards ISO
Data Discovery Module
• No access to PHI or raw/processed
data
• Regional cloud deployments

28. A-ROUND & PROJECTED GROWTH
28

29. OUR JOURNEY SO FAR
29
Our Funding History
2017
Q2
2021
Q2
2022
Longenesis Founded
1.2m USD Seed
Round
540k USD bridge
round
7.3m USD pre-
money valuation
Our Achievements
Both data
discovery and
engagement
products
deployed
Solutions already
scaling up in the
EU and MENA
region (100%
revenue growth
in 2021)
Ongoing
partnership
closing process
with large
customers in the
pipeline
Commercial
capacity
expansion (BD
lead &
marketing
activities) and
legal entity
setup (move
from HK to US)
in preparation
for A-round

30. A-ROUND FUNDING STRATEGY
30
Business
Development
• Scale up presence in the EU and MENA regions, both in pharma and healthcare
sector
• Expansion of existing pharma and governmental use cases
• Further landing of strategic technical partnerships
Product
Development
• Development of new additional features in line with received customer
feedback, such as: [ES TO INTEGRATE]
• Targeted expansion of product team to support new developments and new
potential regulatory requirements
Operations
• Expansion of business development resources to support envisioned growth
• Expansion of business support functions and systems (finance, legal,
compliance) to support growth and A-round requirements
• Additional marketing and customer success resources to enhance company
branding and marketing strategy
A-round envisioned timeline
Q3
2022
Q1
2023
Q2
2023
Completion of
required diligence
5m USD A-round
Phase 1
5m USD A-round
Phase 2
10m USD A-round
at 30m USD pre-
money valuation

31. OUR FINANCIAL PERFORMANCE
31
€ 110,000
€ 280,000
€ 660,000
€ 1,220,000
€ 2,500,000
€ 4,000,000
2020 2021 2022 2023 2024 2025
• >100% growth in 2021
• Group 42 Healthcare (UAE) - 140k
EUR
• Response to Covid projects with LV
and EU partners - 32k and 45k EUR
• Collaboration with research
consortium (EU) and university
hospitals on patient identification
with rare skin diseases - 105k EUR
2020-21 Results
• 100% YoY growth by converting
pilots into large paying customers
and scaling-up our international reach
• See following slide for key accounts
strategy details
Strategic Plan
Actuals
Forecast

32. 2022-23 COMMERCIAL FOCUS
32
€ -
€ 100,000
€ 200,000
€ 300,000
€ 400,000
G42 (secured) Intel FL (trial
pending)
IROS
(agreement
pending)
Alexion (trial
pending)
Intel Neom
(agreement
pending)
Others
Our main accounts
2022 2023
• closing international
pilots and building our
user base through their
networks
2022 Focus
• converting pilots into
large paying customers
and scaling-up our
international reach
2023 Focus

33. CUSTOMER SUCCESS & SCALABILITY
33
Avg. deployment time (days) N. of filled surveys Avg. survey / day
35 (11 for the last two
projects)
>110
0.5 (2.5 for the last two
projects)
N. of Data Publishers
Data Publishers with
uploaded data
N. of covered
therapeutic areas
Avg. deployment
time (days)
30 >50% >10 20
Capturing customer feedback and scaling up quickly

34. OUR SCALABLE PARTNERSHIP BUSINESS MODEL
34
Deploy Curator and Engage in a disease-
specific clinical study for data discovery and
participant engagement
Partnership Opportunities
Use Curator with
existing network of
sponsor’s sites, use
Engage to engage
participants
Use Curator to
discover new sites
in a specific area,
use Engage to
engage participants
Build together a
use case with
Curator to bring
together sites in
scope, use Engage
to engage
participants
Our Business Model
Partnership with Pharma / CRO
Flat fixed fee
for Curator
access
SaaS tiered
pricing for
Engage access,
depending on
participant
cohort

35. APPENDIX AND SELECTED CASE STUDIES
35

36. EFFICIENT IDENTIFICATION AND MULTI-MODAL DIAGNOSTIC
SYSTEM FOR RARE SKIN DISEASES
36
Partner
Challenge
Need for a new screening system and clinical testing for
effective diagnosis of patients with undiagnosed rare skin
diseases.
Achievements
Developed a new screening system combines tools for
patient identification – Engage and Curator, followed by
multimodal dermatoscopic evaluation.
System is based on a dynamic survey module, where active
clinicians in hospitals can quickly and easily describe
patients' diagnostic criteria, disease history, and insights
from anywhere in the world

37. MECHANISMS OF COPING WITH PANDEMIC-INDUCED
INDIVIDUAL ECONOMIC SHOCKS
37
Partner
Challenge
Understand the impact of economic shocks and uncertainty
on long-term mental health
Achievements
Longenesis Engage digitally engages participants in the
study and provides a platform in multiple languages.
Project is carried out as a collaboration of the seven
European universities within the framework of FORTHEM-
Alliance

38. INDIVIDUAL APPROACH IN THE TREATMENT OF MULTIPLE
SCLEROSIS PATIENTS
38
Partner
Challenge
Provide researchers with a robust tool for medical
treatment outcome monitoring and enables the participants
to oversee their data.
Achievements
The solution ensures a smoother engagement process via
digital onboarding and follow-up communication.

39. TRACKING THE LONG COVID SYMPTOMS DIGITALLY
39
Partner
Challenge
Develop a survey to help identify different post-COVID
conditions based on regular parent evaluation of their
children's symptoms.
Provide an anonymise collected data overview without
compromising privacy.
Achievements
Engage enables triage of patients for whether they can
continue to recover at home or pursue an appointment with
a medical professional.
Curator enables increased proximity to vital data for
biomedical research and eliminated the need for additional
integrations or third-party data access

40. A MULTI-CENTRE QOL STUDY AMONG TYPE 1 DIABETICS FOR
MARKET ACCESS & CHANGES IN REIMBURSEMENT STRATEGY
40
Partner
Medtronic, Children University hospital, University of
Latvia
Challenge
Time-constrained QoL data gathering for market access
package
Achievements
120+ patients identified via Curator and engaged in the
study
Patients were motivated by dynamic consent tool and
being proactively engaged
High retention for follow-ups >80%
Delighted customer

41. FEDERATING LEARNING - ENABLING OF LOCAL AI MODEL
TRAINING FOR A MAJOR PHARMA CLIENT IN PEDIATRICS
41
Partner
Global Pharma + Leading Tech Company + several
pediatric hospitals
Challenge
Need to discover data for local AI model training
Need to obtain relevant patient permissions for data usage
Achievements
Data successfully discovered in multiple pediatric
“federations”
Data used for AI training with patient permissions obtained

42. RWD MARKET ACCESS STUDY ON THE USE OF ORAL
CONTRACEPTIVES
42
Partner EU-based Pharma with a portfolio of fertility products
Challenge
Inability to gather data among pre-screening population
Lack of proactive engagement of population
Achievements
6000+ female participants engaged in personalized risk
assessment and prospective RWD studies
Platform provides ability to validate any public health and
disease-specific hypothesis in real-time